PCWA
KNTE

Pacific Capital Wealth Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Pacific Capital Wealth Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$237 – 541
2023
Q4 		$237 Buy
+100
New +$177 ﹤0.01% 323

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacific Capital Wealth Advisors's KNTE Position: Q1 2024 in Review

Pacific Capital Wealth Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 100 shares — an estimated $237 sold.

Pacific Capital Wealth Advisors first reported a position in KNTE in Q4 2023 and held it in 1 quarter. The position peaked at $237 in Q4 2023. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Pacific Capital Wealth Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Pacific Capital Wealth Advisors sold 100 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $237.
  • Pacific Capital Wealth Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Pacific Capital Wealth Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $237 in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Pacific Capital Wealth Advisors's 13F filing for Q1 2024, filed 15 May 2024.